Novo Nordisk stock just had its worst day since Black Monday, after the maker of Ozempic and Wegovy slashed its 2025 outlook.

La farmacéutica danesa espera un crecimiento menor, lo que supone su segundo recorte de estimaciones en lo que va de año

The Danish weight loss drug-maker claims "knock-off" treatments are hitting growth.

Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy

Nuovo tonfo alla borsa di Copenaghen per il gigante danese. A contribuire all'incertezza degli investitori il cambio al vertice e l'ingresso di nuovi competitor

Novo Nordisk stock just had its worst day since Black Monday, after the maker of Ozempic and Wegovy slashed its 2025 outlook.